title: Is Helicobacter pylori eradication a cost-effective treatment of duodenal ulcer disease?
abstract: Treatment strategies aimed at eradicating Helicobacter pylori have shown positive results in the management of duodenal ulcer disease. Several cost-effectiveness studies comparing these regimens with traditional therapy have recently been conducted, and results are discussed in this review. Cost comparisons of different treatment strategies cannot be performed without first identifying whether the cost of ulcer diagnosis is included in the study. Assuming that only 20% of patients with dyspepsia actually have ulcer disease, costs may vary, depending on the study population. Importantly, treatment costs should not be compared between a patient population with confirmed ulcer disease and one without confirmed disease. In patients with confirmed ulcer disease, studies consistently show that H. pylori eradication strategies are associated with greater efficacy and lower costs than traditional treatment, and are therefore a more cost-effective alternative to standard therapy. Although all models used in the cost-effectiveness analyses assume that patients discontinue treatment following successful eradication of the microorganism, in clinical practice some patients continue antisecretory treatment beyond this period. Thus, savings as a result of H. pylori eradication may be less substantial than indicated in cost-effectiveness studies.
authors.affiliation: Department of Health Economics, Université Lyon I, Villeurbanne, France.
authors.forename: M O
authors.initials: MO
authors.lastname: Carrere
authors.forename: H
authors.initials: H
authors.lastname: Lamouliatte
authors.forename: P
authors.initials: P
authors.lastname: Ruszniewski
mesh_terms: D003362:Cost-Benefit Analysis; D003663:Decision Trees; D004381:Duodenal Ulcer / Q000188:drug therapy*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008390:Markov Chains